Bowman, J.E. 1995. Presentation to the IOM Conference on Xenograft Transplantation: Science, Ethics, and Public Policy. June 25-27.

Caplan, A.L. 1992. Is xenografting morally wrong? Transplant. Proc. 24(2):722-727.

Chapman, L.E. 1995. Presentation to the IOM Conference on Xenograft Transplantation: Science, Ethics, and Public Policy. June 25-27.

Chapman, L.E., T.M. Folks, D.R. Salomon, A.P. Patterson, T.E. Eggerman, and P.D. Noguchi. 1995. Xenotransplantation and xenogeneic infections. N. Engl. J. Med. 333(22):1498-1501.

Cooper, D.K.C. 1995. Presentation to the IOM Conference on Xenograft Transplantation: Science, Ethics, and Public Policy. June 25-27.

Cooper, D.K.C., E. Koren, and R. Oriol. 1994. Oligosaccharides and discordant xenotransplantation. Immunol. Rev. 141:31-58.


Dalmasso, A.P., G.M. Vercellotti, J.L. Platt, and F.H. Bach. 1991. Inhibition of complement-mediated endothelial cell cytotoxicity by decay-accelerating factor. Potential for prevention of xenograft hyperacute rejection. Transplantation 52:530-533.

Dresser, R. 1995. Presentation to the IOM Conference on Xenograft Transplantation: Science, Ethics, and Public Policy. June 25-27.


Evans, R.W. 1989. Money matters: Should ability to pay ever be a consideration in gaining access to transplantation? Transplant. Proc. 21:3419-3423.

Evans, R.W. 1993. Organ transplantation and the inevitable debate as to what constitutes a basic health care benefit. Pp. 359-391 in P.I. Terasaki and J.M. Cecka (Eds.), Clinical Transplantation 1993. Los Angeles: UCLA Tissue Typing Laboratory, UCLA School of Medicine.

Evans, R.W. 1995a. Liver transplantation in a managed care environment. Liver Trans. Surg. 1:61-75.

Evans, R.W. 1995b. Presentation to the IOM Conference on Xenograft Transplantation: Science, Ethics, and Public Policy. June 25-27.

Evans, R.W., C.R. Blagg, and F. Bryan. 1981. Implications for health care policy: A social and demographic profile of hemodialysis patients in the U.S. JAMA 245:487-491.


Faustman, D. 1995. Strategy for successful xenograft survival: Designer modification of cells, tissues and organs. Presentation to the IOM Conference on Xenograft Transplantation: Science, Ethics, and Public Policy. June 25-27.

Faustman, D., and C. Coe. 1991. Prevention of xenograft rejection by masking donor HLA class 1 antigens. Science 252:1700-1702.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement